Market Cap 10.82B
Revenue (ttm) 10.90M
Net Income (ttm) -322.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,956.88%
Debt to Equity Ratio 0.00
Volume 1,978,400
Avg Vol 5,415,760
Day's Range N/A - N/A
Shares Out 150.68M
Stochastic %K 93%
Beta 0.90
Analysts Sell
Price Target $73.25

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stag...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 401 7900
Address:
10578 Science Center Drive, Suite 125, San Diego, United States
wwmeinc
wwmeinc Dec. 12 at 9:43 PM
$RNA .....Guessing somebody got ahold of the 'news' between the RNA HQ and the "SEC" filing office today :) glta https://www.sec.gov/cgi-bin/browse-edgar?company=AVIDITY+BIOSCIENCES&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany "The Company Business evaluated subsequent events to assess the need for potential recognition and disclosure in this report through December 10, 2025, the date on which these condensed combined financial statements were available to be issued. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed combined financial statements, other than those described in Note 1."
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:37 PM
Actionable Trade Alert for $RNA Market Context: $RNA is currently trading at $71.6, close to its 60D high of $71.79. The RSI at 67.92 indicates that the stock is nearing overbought territory, suggesting caution. However, the price remains above the 30-day moving average (MA30) of 70.81, indicating a bullish trend. Directional Bias: The bullish sentiment is supported by the MA30 being above the MA50 (63.08). This suggests that short-term momentum is strong relative to the medium-term trend. The proximity to the 60D high also indicates potential for further upside. Trade Plan: - Suggested Entry: $71.6 - Stop Loss: $69.5 (approximately 2.9% below entry) - Take Profit Targets: - TP1: $73.5 (2.65% gain) - TP2: $75.0 (4.25% gain) - TP3: $83.5 (16.6% gain) This plan offers a potential ROI of over 17% on TP3 while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:40 AM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.3, showing bullish momentum as indicated by the RSI of 58.56, which is approaching overbought territory but still has room for upward movement. The price is above the 30-day moving average (MA30) of 70.7 and significantly above the 50-day moving average (MA50) of 61.95, suggesting a strong bullish trend. Directional Bias: The recent high of $71.79 indicates a resistance level, while the low of $38.94 provides a solid support base. Given the current price is near the 60-day high, there is potential for a breakout. Trade Plan: - Suggested Entry: $71.5 - Stop Loss: $68.5 (3.9% below entry) - Take Profit Targets: - TP1: $73.5 (3.0% gain) - TP2: $75.0 (4.2% gain) - TP3: $83.5 (17% gain) This plan allows for a solid risk-to-reward ratio, with TP3 offering a significant return. Monitor the trade closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:28 PM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.21, showing bullish momentum as it is near its 60D high of $71.79. The RSI at 59.54 indicates that the stock is neither overbought nor oversold, suggesting potential for further upward movement. The MA30 at $70.66 is providing support, while the MA50 at $61.38 indicates a strong bullish trend. Directional Bias: The stock is in a bullish phase, supported by its proximity to the 60D high and the positive trend indicated by the moving averages. Trade Plan: - Suggested Entry: $71.25 - Stop Loss: $69.50 (1.5% below entry) - Take Profit Targets: - Target 1: $73.00 (2.5% ROI) - Target 2: $75.00 (5.5% ROI) - Target 3: $83.50 (17.3% ROI) This setup offers a solid risk-reward ratio with significant upside potential. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:28 AM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.54, showing strength as it approaches the 60D high of $71.78. The RSI at 64.23 indicates bullish momentum, but caution is warranted as it is nearing overbought territory. The MA30 at $69.15 and MA50 at $60.20 suggest a strong uptrend. Directional Bias: Bullish. The price is above both the MA30 and MA50, indicating positive momentum. The proximity to the 60D high supports a bullish outlook, but the RSI suggests a potential pullback may occur. Trade Plan: - Suggested Entry: $71.54 - Stop Loss: $69.00 (below MA30) - Take Profit Targets: 1. $73.00 (3% gain) 2. $75.00 (4.3% gain) 3. $83.50 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the trade closely, especially with the RSI nearing overbought levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:03 PM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.54, showing strength as it approaches the 60D high of $71.78. The RSI at 64.23 indicates bullish momentum, but caution is warranted as it is nearing overbought territory. The MA30 at $69.15 and MA50 at $60.20 suggest a strong uptrend. Directional Bias: Bullish. The price is above both the MA30 and MA50, indicating positive momentum. The proximity to the 60D high supports a bullish outlook, but the RSI suggests a potential pullback may occur. Trade Plan: - Suggested Entry: $71.54 - Stop Loss: $69.00 (below MA30) - Take Profit Targets: 1. $73.00 (3% gain) 2. $75.00 (4.3% gain) 3. $83.50 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the trade closely, especially with the RSI nearing overbought levels. https://privateprofiteers.com
0 · Reply
vic_li38
vic_li38 Dec. 4 at 2:32 PM
$RNA push!
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 10:15 AM
$RNA Current Stock Price: $71.58 Contracts to trade: $70 RNA Dec 19 2025 Call Entry: $1.71 Exit: $2.59 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
wwmeinc
wwmeinc Dec. 3 at 6:15 PM
$RNA ......We might be getting close for the Co. to finalize a Date of Record....so far that last SEC filing(Nov.24/25) was just a preliminary release....nothing 'set in stone' in regards to vote,etc...Choice now to sell and move capital elsewhere or hang-tight for the record date and SpinOut news/shares....after the vote of course...glta
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 4:42 PM
$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥
0 · Reply
Latest News on RNA
3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 6 weeks ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP


Why Avidity Biosciences Stock Blasted 42% Higher Today

Oct 27, 2025, 5:12 PM EDT - 6 weeks ago

Why Avidity Biosciences Stock Blasted 42% Higher Today


Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 10:22 AM EDT - 6 weeks ago

Is it too late to buy Avidity stock after Novartis deal?


Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 6 weeks ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS


Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 6 weeks ago

Novartis to acquire Avidity Biosciences for about $12B

NVS


Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 6 weeks ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS


Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 6 weeks ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS


Avidity (RNA) Q2 Revenue Jumps 88%

Aug 7, 2025, 6:19 PM EDT - 4 months ago

Avidity (RNA) Q2 Revenue Jumps 88%


wwmeinc
wwmeinc Dec. 12 at 9:43 PM
$RNA .....Guessing somebody got ahold of the 'news' between the RNA HQ and the "SEC" filing office today :) glta https://www.sec.gov/cgi-bin/browse-edgar?company=AVIDITY+BIOSCIENCES&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany "The Company Business evaluated subsequent events to assess the need for potential recognition and disclosure in this report through December 10, 2025, the date on which these condensed combined financial statements were available to be issued. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed combined financial statements, other than those described in Note 1."
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:37 PM
Actionable Trade Alert for $RNA Market Context: $RNA is currently trading at $71.6, close to its 60D high of $71.79. The RSI at 67.92 indicates that the stock is nearing overbought territory, suggesting caution. However, the price remains above the 30-day moving average (MA30) of 70.81, indicating a bullish trend. Directional Bias: The bullish sentiment is supported by the MA30 being above the MA50 (63.08). This suggests that short-term momentum is strong relative to the medium-term trend. The proximity to the 60D high also indicates potential for further upside. Trade Plan: - Suggested Entry: $71.6 - Stop Loss: $69.5 (approximately 2.9% below entry) - Take Profit Targets: - TP1: $73.5 (2.65% gain) - TP2: $75.0 (4.25% gain) - TP3: $83.5 (16.6% gain) This plan offers a potential ROI of over 17% on TP3 while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:40 AM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.3, showing bullish momentum as indicated by the RSI of 58.56, which is approaching overbought territory but still has room for upward movement. The price is above the 30-day moving average (MA30) of 70.7 and significantly above the 50-day moving average (MA50) of 61.95, suggesting a strong bullish trend. Directional Bias: The recent high of $71.79 indicates a resistance level, while the low of $38.94 provides a solid support base. Given the current price is near the 60-day high, there is potential for a breakout. Trade Plan: - Suggested Entry: $71.5 - Stop Loss: $68.5 (3.9% below entry) - Take Profit Targets: - TP1: $73.5 (3.0% gain) - TP2: $75.0 (4.2% gain) - TP3: $83.5 (17% gain) This plan allows for a solid risk-to-reward ratio, with TP3 offering a significant return. Monitor the trade closely and adjust as necessary. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:28 PM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.21, showing bullish momentum as it is near its 60D high of $71.79. The RSI at 59.54 indicates that the stock is neither overbought nor oversold, suggesting potential for further upward movement. The MA30 at $70.66 is providing support, while the MA50 at $61.38 indicates a strong bullish trend. Directional Bias: The stock is in a bullish phase, supported by its proximity to the 60D high and the positive trend indicated by the moving averages. Trade Plan: - Suggested Entry: $71.25 - Stop Loss: $69.50 (1.5% below entry) - Take Profit Targets: - Target 1: $73.00 (2.5% ROI) - Target 2: $75.00 (5.5% ROI) - Target 3: $83.50 (17.3% ROI) This setup offers a solid risk-reward ratio with significant upside potential. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:28 AM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.54, showing strength as it approaches the 60D high of $71.78. The RSI at 64.23 indicates bullish momentum, but caution is warranted as it is nearing overbought territory. The MA30 at $69.15 and MA50 at $60.20 suggest a strong uptrend. Directional Bias: Bullish. The price is above both the MA30 and MA50, indicating positive momentum. The proximity to the 60D high supports a bullish outlook, but the RSI suggests a potential pullback may occur. Trade Plan: - Suggested Entry: $71.54 - Stop Loss: $69.00 (below MA30) - Take Profit Targets: 1. $73.00 (3% gain) 2. $75.00 (4.3% gain) 3. $83.50 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the trade closely, especially with the RSI nearing overbought levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:03 PM
Actionable Trade Alert for $RNA: Market Context: $RNA is currently trading at $71.54, showing strength as it approaches the 60D high of $71.78. The RSI at 64.23 indicates bullish momentum, but caution is warranted as it is nearing overbought territory. The MA30 at $69.15 and MA50 at $60.20 suggest a strong uptrend. Directional Bias: Bullish. The price is above both the MA30 and MA50, indicating positive momentum. The proximity to the 60D high supports a bullish outlook, but the RSI suggests a potential pullback may occur. Trade Plan: - Suggested Entry: $71.54 - Stop Loss: $69.00 (below MA30) - Take Profit Targets: 1. $73.00 (3% gain) 2. $75.00 (4.3% gain) 3. $83.50 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the trade closely, especially with the RSI nearing overbought levels. https://privateprofiteers.com
0 · Reply
vic_li38
vic_li38 Dec. 4 at 2:32 PM
$RNA push!
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 10:15 AM
$RNA Current Stock Price: $71.58 Contracts to trade: $70 RNA Dec 19 2025 Call Entry: $1.71 Exit: $2.59 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
wwmeinc
wwmeinc Dec. 3 at 6:15 PM
$RNA ......We might be getting close for the Co. to finalize a Date of Record....so far that last SEC filing(Nov.24/25) was just a preliminary release....nothing 'set in stone' in regards to vote,etc...Choice now to sell and move capital elsewhere or hang-tight for the record date and SpinOut news/shares....after the vote of course...glta
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 4:42 PM
$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥
0 · Reply
wwmeinc
wwmeinc Dec. 2 at 1:38 AM
$VKTX $IOVA $RNA ....A 'drawback' of receiving an CVR.....courts will now decide if Bristol played 'fast and losse' with the concept....this is why cash is always king...saves any questionable moves by the buyer from coming to bear on shareholders waiting to get paid for a future event...data delay.etc...A promisary note that really is only backed up by the good faith of the issuer.....the courts will decide if this/was the case though...should be an interesting tale though...glta https://www.reuters.com/world/bristol-myers-must-face-67-billion-lawsuit-over-delayed-cancer-drug-us-judge-2025-12-01/
1 · Reply
quickaspeter
quickaspeter Nov. 26 at 4:35 PM
$RNA $SRPT $TSHA Amazing…❤️💥🚀💰
0 · Reply
wwmeinc
wwmeinc Nov. 26 at 3:25 PM
$VKTX ...For sure.....and with everybody and their mothers and grandparents all looking for that next buy-out candidiate after the great drama PFE/MTSR/NVO gave the mkt/sector....Brian is most likely kicking out the low-ballers as we speak...once they get into office though. What is a bit interesting, is this 'cone of silence' that has dropped on these bidders....Guessing, the lawyers have laid down the law to all employees/bankers/advisors, which in turn shuts out those pesky fin'l reporters looking for the next $RNA scoop...hmmm....just need one...just one to slip under this cone...;) Oh well...just a matter of when not if we get this release...Thanks. glta "In summary, while NVO and LLY currently dominate the market with effective, once-weekly injectable treatments, VKTX is a potential disruptor due to its comparable efficacy data in earlier trials and the potential for a more convenient, less frequent dosing schedule"
2 · Reply
wwmeinc
wwmeinc Nov. 25 at 5:54 PM
$RNA ...Noticed how the two Investment bankers/advisors(Barclays and Goldman).....used the WS analysts price targets as a bit of info/data gathering when calculating a 'value' for Sarah/BOD to bring to shareholders....with the final being $72 cash....just saying...and a SpinCo....with its $1.58 handle(pre-listing though)....w/$270M in the bank to boot...that being said...those 350+ pages got to the eyes last night ;) In the end...cash is king, bigtime! Thanks. glta ***Those FT finance reporters....they really deserve all the credit, for my case at least. If I ever looked or had $RNA in one of the watchlists...I cannot remember if I actually ever "re-visited" them before those FT reporters dropped the rumour....still, DD is a requirement...as nothing is guaranteed with biotech's.
0 · Reply
JFais
JFais Nov. 25 at 5:07 PM
$RNA $MDGL Congrats on the W @JoseRestonVA Respect the patience & risk mgmt 👏
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 25 at 4:17 PM
Fascinating play by play released SEC filings by and between $RNA and $NVS from July until Ovorvet. Recall the chemo centrix back and forth w $AMGN and realized these deals hinge on 1-2 key attributes. $IFRX $AZN
1 · Reply
dgbio
dgbio Nov. 25 at 6:36 AM
$RNA Reading merger proxy: • There were several other buyers expressing interest but also saying they need more time. • The deal is done via shareholder vote and not by tender which is faster. • Avidity is able 'in certain circumstances, to furnish information to and conduct negotiations with a third party regarding a bona fide written, unsolicited, alternative Acquisition Proposal (as defined in the section of this proxy statement entitled “The Merger Agreement—Certain Definitions” beginning on page 110) that the Board determines in good faith, after consulting with its outside legal counsel and financial advisors, constitutes or could reasonably be expected to lead to a Superior Proposal'. =>Superior offer remains possible.
0 · Reply
dgbio
dgbio Nov. 25 at 12:10 AM
$RNA Reading merger proxy: first proposal - $52, second proposal - $60, third proposal - $70, final proposal - $72 + SpinCo. Did a financing because Novartis was conditioning proposal on certain DD results. Said no to this, cut Novartis off the data room and did $500M financing. Boyce is really good. Whatever she does next, I want a share in it.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 24 at 10:34 PM
@outlawinvestor1 Hey man $RNA filed its 14A today. As you probably know, RNA was acquired for roughly $12B. I have not done the work yet but it appears the enterprise value is roughly $10B (but I need to do the math). Gross margins are forecast to be in the mid-80s (85% at peak). The RNA EV appears to be, more or less, 1X peak sales. I have to leave for the day. I'll compare to the oncology companies tomorrow morning. $XBI $IBB $NBI FYI only.
1 · Reply
wwmeinc
wwmeinc Nov. 24 at 5:29 PM
$RNA $TSHA $SRPT This gene news today out of the UK has given the space/sector some good coverage...not company specific per se...charity funding kept the science going in the end...just good/great to see science coming through....glta "In 2020 the university announced a partnership with a small US biotech company Avrobio, to conduct a clinical trial. But three years later the company handed back the licence to the university, following poor results from another gene therapy study and a lack of funds. The first-in-human trial, which would soon help Oliver, was in jeopardy before it had even begun. Prof Jones: "We had to move very quickly to try to save the whole idea and find another sponsor and another source of funding." It was then that British medical research charity, LifeArc, stepped in, providing £2.5m of funding." https://www.bbc.com/news/articles/c5y0y56x6veo
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 5:24 PM
0 · Reply
Ohzipit
Ohzipit Nov. 19 at 11:53 PM
$VKTX in a 3 month period $RNA traded from high 20s to low 50s on takeover speculation. Within weeks it Was taken back to the 20s on no news and a month and a half later bought for $12 Billion. For institutions the only thing better than making a lot of money is making it multiple times on the same deal. IMO the stock should have traded back over recent highs on today’s news…it’s coming and it will be glorious.
0 · Reply